| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-07 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-07 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-07 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.16 | 8e-07 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.16 | 9e-07 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.25 | 2e-06 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 2e-05 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.13 | 4e-05 |